Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed By Related or Unrelated Donor Hematopoietic Cell Transplantation For Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.

Trial Profile

Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed By Related or Unrelated Donor Hematopoietic Cell Transplantation For Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Fludarabine (Primary) ; Rituximab (Primary) ; Ciclosporin; Mycophenolate mofetil
  • Indications Chronic lymphocytic leukaemia; Graft-versus-host disease; Lymphoma; T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms ND
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Jun 2012 New source identified and integrated (Mayo Clinic).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top